Download PDF
Aktuelle Ernährungsmedizin 2016; 41(02): 113-117
DOI: 10.1055/s-0042-102160
Viewpoint
© Georg Thieme Verlag KG Stuttgart · New York

Die metabolische Selbstzerstörung des kritisch kranken Patienten (Teil II): Die Bedeutung der modernen Medizin und therapeutische Konsequenzen[1] [2]

Metabolic Self-Destruction in Critically Ill Patients (Part II): The Importance of Modern Medical Care and Therapeutic Consequences
W. H. Hartl
Klinik für Allgemeine, Viszeral-, Transplantations-, Gefäß- und Thoraxchirurgie, Campus Großhadern, LMU München
› Author Affiliations
Further Information

Publication History

Publication Date:
11 April 2016 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die moderne Medizin (Intensiv- und Notfallmedizin) ermöglicht das akute Überleben eines Patienten auch nach sehr schwerer Homöostasestörung. Dieser Fortschritt hat jedoch die Nützlichkeit von prinzipiell vorteilhaften, adaptativen metabolischen Reaktionen (Hyperglykämie, Muskeleiweißkatabolismus) dahingehend modifiziert, dass diese nun in übersteigertem Ausmaß ausgelöst werden und dadurch selbstzerstörerische Wirkungen entfalten können. Potenziell schädliche Nebenwirkungen der metabolischen Reaktionen resultieren aus deren Quantität, welche durch Intensität und Dauer der Homöostasestörung bestimmt wird. Adjuvante Therapien wie die künstliche Ernährung können metabolischen Extremreaktionen auf keinen Fall verhindern, sondern allerhöchstens helfen, sekundären Schaden zu minimieren. Eine effektive metabolische Therapie ist nur dann möglich, wenn gleichzeitig die Auslösemechanismen (Trauma, Shock, Sepsis) so aggressiv wie möglich bekämpft werden, um dadurch die metabolischen Triggermechanismen bereits an ihrem Ursprung zu unterbrechen.

Abstract

Modern emergency and intensive care medicine allows patients to survive even extreme disturbances of their homeostasis. This progress, however, has modified utility of originally advantageous metabolic reactions (hyperglycemia, muscle protein catabolism) to a point where their activation is exaggerated thereby revealing auto-destructive elements. Potentially detrimental side effects of metabolic reactions result from their quantity which is determined by extent and duration of the disturbance of homeostasis. Self-destructive metabolic responses cannot be prevented by adjuvant therapies such as artificial nutrition which may only help to ameliorate secondary metabolic damage. Effective treatment is only possible by a simultaneous aggressive therapy of underlying pathologies (such as shock, trauma or infection) thereby interrupting secondary metabolic trigger mechanisms at an early stage.

Schlüsselwörter

schwere Sepsis - Trauma - Schock - Fokus-Eradikation - Hyperglykämie - Eiweißkatabolismus - künstliche Ernährung - intestinales Mikrobiom

Keywords

severe sepsis - trauma - shock - focus eradication - hyperglycemia - protein catabolism - artificial nutrition - gut microbiome

1 Im Original publiziert unter: Hartl WH, Jauch KW. Metabolic self-destruction in critically ill patients: Origins, mechanisms and therapeutic principles. Nutrition 2014 Mar; 30 (3): 261 – 267


2 Nachdruck aus: DIVI Journal 2015; 6: 102 – 107


 

  • Literatur

  • 1 Hartl WH. Die metabolische Selbstzerstörung des kritisch kranken Patienten (Teil I): Evolutionsbiologische Hintergründe, Mechanismen und Sinnhaftigkeit. Aktuel Ernahrungsmed 2016; 41: 40-44
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Fu CY, Wang YC, Wu SC et al. Higher glucose on admission is associated with need for angioembolization in stable pelvic fracture. Am J Emerg Med 2012; 30: 26-31
    CrossrefPubMedGoogle Scholar
  • 3 Heath DF. Glucose, insulin and other plasma metabolites shortly after injury. J Accid Emerg Med 1994; 11: 67-77
    CrossrefPubMedGoogle Scholar
  • 4 Pomerantz WJ, Hashkes PJ, Succop PA et al. Relationship between serum glucose and injury severity score in childhood trauma. J Pediatr Surg 1999; 34: 1494-1498
    CrossrefPubMedGoogle Scholar
  • 5 Nakamura M, Oda S, Sadahiro T et al. Correlation between high blood IL-6 level, hyperglycemia, and glucose control in septic patients. Crit Care 2012; 16: R58
    CrossrefPubMedGoogle Scholar
  • 6 Thorell A, Nygren J, Ljungqvist O. Insulin resistance: a marker of surgical stress. Curr Opin Clin Nutr Metab Care 1999; 2: 69-78
    CrossrefPubMedGoogle Scholar
  • 7 Gletsu N, Lin E, Zhu JL et al. Increased plasma interleukin 6 concentrations and exaggerated adipose tissue interleukin 6 content in severely obese patients after operative trauma. Surgery 2006; 140: 50-57
    CrossrefPubMedGoogle Scholar
  • 8 Reeds PJ, Jahoor F. The amino acid requirements of disease. Clin Nutr 2001; 20 (Suppl. 01) 15-22
    CrossrefPubMedGoogle Scholar
  • 9 Long CL, Schaffel N, Geiger JW et al. Metabolic response to injury and illness: estimating energy and protein needs from indirect calorimetry and nitrogen balance. JPEN 1979; 3: 452-456
    CrossrefPubMedGoogle Scholar
  • 10 Elwyn DH. Protein metabolism and requirements in the critically ill patient. Crit Care Clin 1987; 3: 57-69
    PubMedGoogle Scholar
  • 11 Wilmore DW. Metabolic management of the critically ill. New York: Plenum Press; 1977: 149
    CrossrefGoogle Scholar
  • 12 Cuesta JM, Singer M. The stress response and critical illness: A review. Crit Care Med 2012; 40: 3283-3289
    CrossrefPubMedGoogle Scholar
  • 13 Gentile LF, Cuenca AG, Efron PA et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg 2012; 72: 1491-1501
    CrossrefPubMedGoogle Scholar
  • 14 Doig GS, Simpson F, Sweetman EA et al. Early PN Investigators of the ANZICS Clinical Trials Group. Early parenteral nutrition in critically ill patients with short-term relative contraindications to early enteral nutrition: a randomized controlled trial. JAMA 2013; 309: 2130-2138
    CrossrefPubMedGoogle Scholar
  • 15 National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Rice TW, Wheeler AP, Thompson BT et al. Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. JAMA 2012; 307: 795-803
    CrossrefPubMedGoogle Scholar
  • 16 Heyland D, Muscedere J, Wischmeyer PE et al. Canadian Critical Care Trials Group. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 2013; 368: 1489-1497
    CrossrefPubMedGoogle Scholar
  • 17 Van Zanten AR, Sztark F, Kaisers UX et al. High-protein enteral nutrition enriched with immune-modulating nutrients vs standard high-protein enteral nutrition and nosocomial infections in the ICU: a randomized clinical trial. JAMA 2014; 312: 514-524
    CrossrefPubMedGoogle Scholar
  • 18 Casaer MP, Mesotten D, Hermans G et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med 2011; 365: 506-517
    CrossrefPubMedGoogle Scholar
  • 19 NICE-SUGAR Study Investigators. Finfer S, Chittock DR, Su SY et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-1297
    CrossrefPubMedGoogle Scholar
  • 20 Wolfe RR. Sepsis as a modulator of adaptation to low and high carbohydrate and low and high fat intakes. Eur J Clin Nutr 1999; 53 (Suppl. 01) S136-142
    CrossrefPubMedGoogle Scholar
  • 21 Chambrier C, Laville M, Rhzioual Berrada K et al. Insulin sensitivity of glucose and fat metabolism in severe sepsis. Clin Sci (Lond) 2000; 99: 321-328
    CrossrefPubMedGoogle Scholar
  • 22 Long CL, Nelson KM. Nutritional requirements based on substrate fluxes in trauma. Nutr Res 1993; 13: 1459-1478
    CrossrefPubMedGoogle Scholar
  • 23 Larsson J, Lennmarken C, Mårtensson J et al. Nitrogen requirements in severely injured patients. Br J Surg 1990; 77: 413-416
    CrossrefPubMedGoogle Scholar
  • 24 Ishibashi N, Plank LD, Sando K et al. Optimal protein requirements during the first 2 weeks after the onset of critical illness. Crit Care Med 1998; 26: 1529-1535
    CrossrefPubMedGoogle Scholar
  • 25 Shaw JH, Wildbore M, Wolfe RR. Whole body protein kinetics in severely septic patients. The response to glucose infusion and total parenteral nutrition. Ann Surg 1987; 205: 288-294
    CrossrefPubMedGoogle Scholar
  • 26 Rennie MJ. Anabolic resistance in critically ill patients. Crit Care Med 2009; 37 (Suppl. 10) S398-399
    CrossrefPubMedGoogle Scholar
  • 27 Jensen GL, Mirtallo J, Compher C et al. International Consensus Guideline Committee. Adult starvation and disease-related malnutrition: a proposal for etiology-based diagnosis in the clinical practice setting from the International Consensus Guideline Committee. JPEN J Parenter Enteral Nutr 2010; 34: 156-159
    CrossrefPubMedGoogle Scholar
  • 28 Schetz M, Casaer MP, Van den Berghe G. Does artificial nutrition improve outcome of critical illness?. Crit Care 2013; 17: 302
    PubMedGoogle Scholar
  • 29 Stroud M. Protein and the critically ill; do we know what to give?. Proc Nutr Soc 2007; 66: 378-383
    CrossrefPubMedGoogle Scholar
  • 30 Heidegger CP, Berger MM, Graf S et al. Optimisation of energy provision with supplemental parenteral nutrition in critically ill patients: a randomised controlled clinical trial. Lancet 2013; 381: 385-393
    CrossrefPubMedGoogle Scholar
  • 31 Mirnezami R, Kinross JM, Vorkas PA et al. Implementation of molecular phenotyping approaches in the personalized surgical patient journey. Ann Surg 2012; 255: 881-889
    CrossrefPubMedGoogle Scholar
  • 32 Siegelaar SE, Hermanides J, Oudemans-van Straaten HM et al. Mean glucose during ICU admission is related to mortality by a U-shaped curve in surgical and medical patients: a retrospective cohort study. Crit Care 2010; 14: R224
    CrossrefPubMedGoogle Scholar
  • 33 Hart DW, Wolf SE, Chinkes DL et al. Effects of early excision and aggressive enteral feeding on hypermetabolism, catabolism, and sepsis after severe burn. J Trauma 2003; 54: 755-761
    CrossrefPubMedGoogle Scholar
  • 34 Rüttinger D, Kuppinger D, Hölzwimmer M et al. Acute prognosis of critically ill patients with secondary peritonitis: the impact of the number of surgical revisions, and of the duration of surgical therapy. Am J Surg 2012; 204: 28-36
    CrossrefPubMedGoogle Scholar
  • 35 Chaudery M, Clark J, Wilson MH et al. Traumatic intra-abdominal hemorrhage control: has current technology tipped the balance toward a role for prehospital intervention?. J Trauma Acute Care Surg 2015; 78: 153-163
    CrossrefPubMedGoogle Scholar
  • 36 Disseldorp LM, Nieuwenhuis MK, Van Baar ME et al. Physical fitness in people after burn injury: a systematic review. Arch Phys Med Rehabil 2011; 92: 1501-1510
    CrossrefPubMedGoogle Scholar
  • 37 Carli F. Postoperative metabolic stress: interventional strategies. Minerva Anestesiol 2006; 72: 413-418
    PubMedGoogle Scholar
  • 38 Deitch EA. Gut-origin sepsis: evolution of a concept. Surgeon 2012; 10: 350-356
    CrossrefPubMedGoogle Scholar
  • 39 Nieves E, Tobón LF, Ríos DI et al. Bacterial translocation in abdominal trauma and postoperative infections. J Trauma 2011; 71: 1258-1261
    CrossrefPubMedGoogle Scholar
  • 40 Yatsunenko T, Rey FE, Manary MJ et al. Human gut microbiome viewed across age and geography. Nature 2012; 486: 222-227
    PubMedGoogle Scholar
  • 41 Kamada N, Chen G, Núñez G. A complex microworld in the gut: Harnessing pathogen-commensal relations. Nat Med 2012; 18: 1190-1191
    CrossrefPubMedGoogle Scholar
  • 42 Boyer AF, Kollef MH. Probiotics for ventilator-associated pneumonia: the need for a large, multicenter, randomized controlled trial. Chest 2013; 143: 590-592
    CrossrefPubMedGoogle Scholar
  • 43 Petrof EO, Dhaliwal R, Manzanares W et al. Probiotics in the critically ill: a systematic review of the randomized trial evidence. Crit Care Med 2012; 40: 3290-3302
    CrossrefPubMedGoogle Scholar
  • 44 Van der Meer JWM, Vandenbroucke-Grauls CMJE. Resistance to selective decontamination: the jury is still out. Lancet Infect Dis 2013; 13: 282-283
    CrossrefPubMedGoogle Scholar
  • 45 Besselink MG, van Santvoort HC, Buskens E et al. Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371: 651-659
    CrossrefPubMedGoogle Scholar
  • 46 Khoruts A, Sadowsky MJ. Therapeutic transplantation of the distal gut microbiota. Mucosal Immunol 2011; 4: 4-7
    CrossrefPubMedGoogle Scholar
  • 47 Van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415
    CrossrefPubMedGoogle Scholar
  • 48 Petrof EO, Gloor GB, Vanner SJ et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome 2013; 1: 3
    CrossrefPubMedGoogle Scholar
  • 49 Bonetto A, Aydogdu T, Jin X et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab 2012; 303: E410-421
    CrossrefPubMedGoogle Scholar
  • 50 Kumar A, Bhatnagar S, Paul PK. TWEAK and TRAF6 regulate skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care 2012; 15: 233-239
    CrossrefPubMedGoogle Scholar
  • 51 Bhatnagar S, Kumar A. The TWEAK-Fn14 system: breaking the silence of cytokine-induced skeletal muscle wasting. Curr Mol Med 2012; 12: 3-13
    CrossrefPubMedGoogle Scholar